Filing Flows › Travere Therapeutics (TVTX) › Q3 2026
Travere Therapeutics (TVTX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Travere Therapeutics (TVTX) reported revenue of $225M for the third quarter 2026 (Q3 2026), +36% from a year earlier and +32% from the quarter before. Operating margin was -30.3%, net loss $52.3M (23.3% of revenue).
Travere Therapeutics, Q3 2026: revenue $225M (+36% year over year), operating margin -30.3%, net loss $52.3M, operating cash flow $98.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $225M | +32% | +36% |
| Operating profit | −$68.1M | -1822% | -373% |
| Net earnings | −$52.3M | — | -304% |
| Operating cash flow | $98.2M | +69% | +586% |
What changed
Revenue was $224.6M in Q3 2026, up 36% year over year and up 32% from the previous quarter. FILSPARI was the largest line at 89% of revenue. FILSPARI added $109.3M year over year (up 120%), 183% of the total change. License and collaboration revenue declined 92%.
Operating costs exceeded revenue by $68.1M, an operating margin of -30.3%. Total costs grew 109% against revenue growth of 36%. The fastest-growing cost line was Other operating costs (+686%). The quarter ended with a net loss of $52.3M, wider than the previous quarter's $34.8M loss.
Operating cash flow was $98.2M (up 586% year over year). Non-cash charges added back $5.2M of depreciation and amortization and $23.4M of share-based compensation. Working capital and other items added $121.9M.
Questions
What was Travere Therapeutics' revenue in the third quarter 2026?
Travere Therapeutics (TVTX) reported revenue of $225M for the third quarter 2026 (Q3 2026), +36% from a year earlier and +32% from the quarter before.
Was Travere Therapeutics profitable in the third quarter 2026?
Operating loss was $68.1M (-30.3% of revenue) and net loss $52.3M.